| Original language | English (US) |
|---|---|
| Pages (from-to) | 274-282 |
| Number of pages | 9 |
| Journal | The journal of prevention of Alzheimer's disease |
| Volume | 7 |
| Issue number | 4 |
| DOIs | |
| State | Published - Aug 1 2020 |
ASJC Scopus subject areas
- Clinical Neurology
- Psychiatry and Mental health
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: The journal of prevention of Alzheimer's disease, Vol. 7, No. 4, 01.08.2020, p. 274-282.
Research output: Contribution to journal › Review article › peer-review
}
TY - JOUR
T1 - A Framework for Developing Pharmacotherapy for Agitation in Alzheimer’s disease
T2 - Recommendations of the ISCTM Working Group
AU - ISCTM: International Society for CNS Clinical Trials and Methodology
AU - O’Gorman, Cedric
AU - Khoury, R.
AU - Anderson, A.
AU - Carter, M.
AU - DiCesare, F.
AU - Dubé, S.
AU - Ereshefsky, L.
AU - Grossberg, G.
AU - Hefting, N.
AU - Khan, S.
AU - Lind, S.
AU - Moebius, H.
AU - Shiovitz, T.
AU - Rosenberg, P.
N1 - Funding Information: Conflict of interests: COG is an employee of Axsome Therapeutics, Inc. MC and SK are full-time employees of Pfizer Inc. SD is a full-time employee of Avanir Pharmaceuticals, Inc. LE holds chief scientific officer positions at Hassman Reseach Institute and CNS Network. GG is a consultant for Acadia, Alkahest, Allergen, Avanir, Axovant, Bioxcel, GE, Genentech, Lundbeck, Novartis, Otsuka, Roche and Takeda; has received research support from Janssen, Roche and the National Institute of Aging (NIA); has been on safety monitoring committees for EryDel, Merck and Newron; and is on a speaker bureau for Acadia. NH and SL are full-time employees of Lundbeck. HM is co-founder and acting CMO at Exciva GmbH. PR has received support for this work through grants 5R01AG054771 and 5R01AG050515-03 from the National Institute of Aging (NIA) and has received support for other research from Eli Lilly, the Alzheimer’s Association and the NIA. No other disclosures were reported.
PY - 2020/8/1
Y1 - 2020/8/1
UR - http://www.scopus.com/inward/record.url?scp=85087495460&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087495460&partnerID=8YFLogxK
U2 - 10.14283/jpad.2020.37
DO - 10.14283/jpad.2020.37
M3 - Review article
C2 - 32920630
AN - SCOPUS:85087495460
SN - 2426-0266
VL - 7
SP - 274
EP - 282
JO - The journal of prevention of Alzheimer's disease
JF - The journal of prevention of Alzheimer's disease
IS - 4
ER -